Insight Molecular Diagnostics (IMDX) Current Deferred Revenue (2018)
Insight Molecular Diagnostics' (IMDX) quarterly Current Deferred Revenue came in at $738000.0 in Q2 2018.
Insight Molecular Diagnostics (IMDX) Current Deferred Revenue (2018) Analysis & Trends
Insight Molecular Diagnostics has disclosed Current Deferred Revenue across 1 years of filings, most recently posting $738000.0 for Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Waters | 29,902.70 Bn | 29,902.24 Bn | 1.11 Bn |
| 2 | Thermo Fisher Scientific | 175.99 Bn | 172.74 Bn | 7.74 Bn |
| 3 | Danaher | 129.87 Bn | 124.18 Bn | 3.59 Bn |
| 4 | Idexx Laboratories | 44.75 Bn | 44.55 Bn | 722.74 Mn |
| 5 | Agilent Technologies | 37.52 Bn | 35.72 Bn | 990.00 Mn |
| 6 | Iqvia Holdings | 30.91 Bn | 28.94 Bn | 1.36 Bn |
| 7 | Natera | 30.21 Bn | 29.11 Bn | 696.04 Mn |
| 8 | Illumina | 24.19 Bn | 23.04 Bn | 721.00 Mn |
| 9 | Mettler Toledo International | 23.12 Bn | 23.06 Bn | 555.82 Mn |
| 10 | Insight Molecular Diagnostics | 4.34 Mn | -24.59 Mn | 15,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 738,000.00 |